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Abstract  
There is an ongoing urgent need for new targeted antibacterial compounds with novel mechanisms of 
action for the treatment of infections caused by bacteria that are resistant to currently available materials. 
Since the expression of glycosidase enzymes within bacteria is unequally distributed, glycoside derivatives 
of antibacterial agents offer potential as targeted prodrugs for bacterial infections. Herein we report the 
synthesis and characterisation of four α-D-glycopyranosides and three β-D-glycopyranosides of the broad 
antibacterial agent triclosan, in generally very good synthetic yields, and with excellent purities. Each 
glycoside was analysed to determine its ability to inhibit the growth of a wide range of Gram-negative and 
Gram-positive organisms, including many of clinical significance. All of the triclosan glycosides that were 
synthesized demonstrated antibacterial activity against many of the organisms that were examined. For 
example, β-galactoside (3a) and α-arabinoside (3c) had MIC values of 0.5 µg/ml for several strains of S. 
aureus and S. haemolyticus. The triclosan glycosides were also generally found to be more water soluble 
and much more selective than the underivatized triclosan, making them ideal both for the targeted inhibition 
of bacterial growth and as agents for the selective recovery of bacteria from mixed cultures. In the latter case, 
two Bacillus strains could be identified from various strains of Bacillus and Staphylococcus after inoculation 
onto Nutrient Agar No. 2 with 0.25 µg/ml triclosan-α-D-glucopyranoside (3e).   This glucoside may, 
therefore, be of use for the isolation and identification of the food-poisoning organism Bacillus cereus. 
 
Keywords: antibacterial, prodrug, selective recovery 
Introduction 
The need for new antibacterial compounds to treat human bacterial infections has never been more 
important. The introduction of antibiotics into clinical use represented one of the most significant milestones 
in medicine, and allowed huge advances in areas such as organ transplantation, major surgeries and cancer 
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chemotherapy. However, this extensive use, alongside their widespread misuse, has contributed to the 
spread of antibiotic resistance. Strains of bacteria demonstrating widespread resistance to antibiotics 
(“Multi-drug-resistant”, “Pan-drug-resistant”) are being isolated at an alarming rate (1).  It is estimated that 
by 2050, 10 million lives a year and a cumulative 100 trillion USD of economic output are at risk due to the 
rise of drug-resistant infections.  Even today, 700,000 people die of resistant infections every year (2). In a 
recent WHO study it was found that very few new antibiotics are in the clinical pipeline and most of those 
are modifications of existing classes to which resistant mechanisms are arising. Very few potential treatment 
options were identified for those antibiotic-resistant infections posing the greatest threat to health, including 
drug-resistant tudeculosis which kills around 250,000 people each year (3). 
Triclosan (TCS; 5-chloro-2-[2,4-dichlorophenoxy]phenol) (Figure 1) also known as irgasan is a 
synthetic, non-ionic, bis-aryl antimicrobial which has been shown to have anti-fungal and anti-viral 
properties (4-9). It is non-toxic to humans but has a broad-spectrum of activity inhibiting all commonly 
encountered pathogens. Its mechanism of antibacterial action at higher concentrations is towards the cell 
wall but at lower concentrations it inhibits fatty acid synthesis at the enoyl-acyl carrier protein reductase 
(FabI) step (10-13). Fatty acid synthesis is essential in bacteria and inhibition causes disruption of the cell 
membrane and cell breakdown (14-16).  
Whilst triclosan has been extensively used as a disinfectant and has become widely used in many food 
preparation and household products, its low solubility at physiological pH has limited its antibacterial usage 
to topical treatments. Derivatizing the hydroxyl group, which is an essential functional group for 
antibacterial activity, to form a glycoside would be expected to improve its aqueous solubility and enhance 
its uptake into bacterial cells via active carbohydrate transport mechanisms (17-19) whilst also limiting its 
toxicity to those organisms that are able to remove the sugar using the appropriate glycosidase enzyme. 
Since glycosidases are unevenly distributed throughout bacterial taxa (20-24) these targeted bacterial growth 
inhibitors would offer the advantage of not disturbing the natural bioflora of the patient. The triclosan 
glycosides would also be useful as selective agents in bacterial isolation media, hence allowing more easy 
ideintification of bacterial pathogens in food and clinical samples.  
The aim of this investigation was therefore to synthesise a range of novel α- and β-linked triclosan 
glycosides with enhanced aqueous solubility and targeted antibacterial properties compared with triclosan.  
 
 
Figure 1 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Results and Discussion 
Triclosan-β-D-galactopyranoside (3a), β-D-glucopyranoside (3b) and α-D-arabinopyranoside (3c) 
were each synthesized in two steps as summarised in Scheme 1. The first step involved reaction of the 
bromide donor with triclosan (1) in the presence of 1M NaOH (1.06 eq.) to yield, selectively, the desired 
trans-linked protected glycopyranosides (2a-2c) in generally good yields. These were then deprotected by 
treatment with MeOH and catalytic K2CO3 (0.1 eq.) to afford the required triclosan glycosides (3a-3c) in 
very good to excellent yields (25).  
 
 
 
Scheme I. i) 45 % HBr in AcOH, 0 °C, 1.5-3 h: ii) triclosan (1), 1M NaOH, H2O/ acetone, r.t, 18 h: iii) 
MeOH, K2CO3, r.t, 2-17.5 h.  
 
Synthesis of the thermodynamically favoured α-galacto, gluco and mannopyranosides, and β-
arabinopyranoside (2d, 2e, 2f, 2g respectively), was achieved via glycosidation of the acetate donors under 
thermodynamic conditions. Removal of the acetyl protecting groups was again achieved using catalytic 
amounts of potassium carbonate (0.1 eq.) in the presence of methanol to afford the triclosan glycosides (3d, 
3e, 3f, 3g ) in generally excellent yields. 
 
 
 
Scheme II. i) triclosan (1), BF3.OEt2, CH2Cl2, 0°C- r.t, 18 h: ii) MeOH, K2CO3, r.t, 3h. 
The structures of the synthesized intermediates and final compounds were confirmed by 1H and 13C 
NMR spectroscopy and mass spectrometry. In all cases free triclosan and unreacted sugars could not be 
detected in the final products using HPLC analysis and purities were  ≥97%.  
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The Minimum Inhibitory Concentrations (MICs) for triclosan and its glycosides against a wide range 
of Gram-negative and Gram-positive bacteria, including many of clinical significance, were generated using 
the Bioscreen system. Data is summarized in Table 1 (Gram-negative organisms) and Table 2 (Gram-
positive organisms) below.  
 
Tables 1 and 2 MIC (µg/ml) of triclosan glycosides for a range of Gram-negative and Gram-
positive organisms in Nutrient Broth. 
 Gram-negative 
organism 
No. of 
strains 
Triclosan 
(1) 
β-gal 
(3a) 
β-glu 
(3b) 
α-ara 
(3c) 
α-gal 
(3d) 
α-glu 
(3e) 
α-man 
(3f) 
β-ara 
(3g) 
Aer. hydrophila 1 8 256 >256 128 >256 256 >256 >256 
Cit. freundii  1 0.5 8 64 8 64 4 64 64 
Cr. sakazakii 1 0.5 8 64 8 128 8 128 128 
Ent.  aerogenes 1 0.5 8 64 8 128 8 32 128 
Ent. cloacae 1 0.5 0.5 16 0.5 32 1 8 16 
E. coli 8 0.1-0.5 0.5-32 8-64 0.5-4 16-64 2-8 4-64 8-32 
E. hermanii 1 0.5 2 16 1 32 1 16 32 
Hafnia alvei 1 0.1 0.5 4 0.5 16 1 4 4 
Kleb.  aerogenes 1 0.5 4 32 4 32 2 32 32 
Kleb.  1 0.1 0.5 0.5 0.5 1 1 4 4 
Pr. mirabilis 1 0.5 4 16 4 32 2 16 32 
Pr. vulgaris 1 0.5 8 64 16 64 4 32 128 
Ps. aeruginosa 1 32 >256 >256 >256 >256 >256 >256 >256 
Salmonella 11 0.5-1 2-16 16-32 2-8 32-64 2-8 16-64 32-64 
Ser. marcescens 1 64 >256 >256 >256 >256 >256 >256 >256 
 
 
Gram-positive 
organism 
No. of 
strains 
Underiv. 
triclosan 
(1) 
β-gal 
(3a) 
β-gluc 
(3b) 
α-ara 
(3c) 
α-gal 
(3d) 
α-gluc 
(3e) 
α-man 
(3f) 
β-ara 
(3g) 
B. cereus 1 2 256 256 128 >256 128 256 128 
B. subtilis 1 1 32 256 32 256 32 128 128 
Entero. faecalis 1 8 128 16 128 >256 128 256 256 
Entero. faecium 1 4 >256 >256 256 >256 256 256 256 
S. aureus 8 0.01 0.5 4 - 8 0.5 8 - 16 1 2-8 4 - 8 
S. epidermidis 3 0.01 0.5 8 - 16 0.5 8 - 32 1 4-8 8 - 16 
S. haemolyticus 1 0.01 0.5 16 0.5 16 1 8 128 
S. saprophyticus 1 0.01 8 64 8 64 4 32 64 
Str. agalactiae 1 4 256 256 128 >256 128 128 128 
Str. pneumoniae 1 1 128 128 64 128 32 64 64 
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Str. pyogenes 1 1 128 32 16 256 32 32 32 
Str. viridans 1 4 256 256 128 >256 128 128 128 
 
 
 
From Tables 1 and 2 it can be seen that all of the triclosan glycosides that were synthesized 
demonstrated antibacterial activity against many of the organisms that were examined. In particular, the α-
arabinoside (3c) and β-galactoside (3a) both had MICs of 0.5 µg/ml for several organisms including the 
pathogenic staphylococcal species S. aureus and S. haemolyticus. It is well recognised that Methicillin 
Resistant Staphylococcus aureus (MRSA) can be difficult to treat and often last resort compounds, that may 
have toxic side-effects, are therefore used (26, 27). That S. aureus was one of the most sensitive organisms 
to the triclosan glycosides is therefore particularly significant from a clinical perspective. Moreover, 
although various resistance mechanisms are involved for bacteria, resistance in MRSA is mainly due to the 
production of high levels of β-lactamase (28, 29).  Currently, drugs with toxic side-effects are often used 
(30-32) and hence antibiotics such as those described herein that have a different mode of activity are likely 
to be particularly valuable.  
From Tables 1 and 2 it can also be seen that in contrast to the broad toxicity exhibited by the parent 
triclosan, the toxicities of the triclosan glycosides varied considerably according to the organism. As an 
example, the MIC for triclosan was 0.5 µg/ml for eight Gram-negative organisms but MICs for the α-
arabinoside (3c) for these organisms was from 0.5 to 16 µg/ml. This presumably is a reflection of 
differences in glycosidase activity and/ or transport rates of the arabinoside into the cell, and reinforces the 
hypothesis that derivatisation of triclosan as glycosides is a useful strategy for enhancing selectivity. 
Moreover, since the solubility of the triclosan glycosides in growth media and buffers at physiological pH is 
much improved compared to underivatised triclosan, which is reflected in the calculated cLogP values for 
the hexose glycosides of 3.02 compared to 4.80 for triclosan (33), it should be possible to use the β-
galactoside (3a) and the α-arabinoside (3c) in peroral and parenteral treatments of MRSA infections rather 
than only in topical applications, as is the current case for triclosan. 
Generally if an organism was resistant to free triclosan it was also resistant to glycosides formed from 
it, indicating that any resistance is probably due to rapid efflux of triclosan, or its inability to cause 
disruption to fatty acid biosynthesis rather than poor transport into the cell. Thus, strains of Aeromonas 
hydrophila, Bacillus cereus, Enterococcus faecium, Ps. aeruginosa, S. marcescens, Streptococcus 
agalactiae and Streptococcus viridans all demonstrated MIC of 2 or greater for triclosan and 128 or greater 
for the glycosides. An exception was Enterococcus faecalis with a MIC of 16µg/ml for the β-glucoside (3b); 
only one doubling dilution higher than that for free triclosan. 
 
As the activities of the triclosan glycosides were much more bacterial selective than the 
underivatized triclosan, this also demonstrates their excellent potential for enriching food or clinical 
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specimens for pathogens prior to instrumental, moleular or traditional means of identification. For example, 
the results in Table 2 demonstrate that the addition of triclosan α-arabinoside (3c) in selective enrichment 
broth at 1.0 µg/ml would allow recovery of Salmonellae but inhibit the growth of many organisms that 
outgrow it such as strains of Enterobacter cloacae, Escherichia hermanii, Escherichia coli, Hafnia alvei, 
Klebsiella pneumoniae and Staphylococcus. Triclosan α-mannoside (3f) at 64 µg/ml also demonstrated 
inhibition profiles that would be particularly useful for the selective recovery of Cronobacter sakazakii 
which is of particular concern when present in infant formula milk (34, 35). To determine whether such 
differences in toxicity of the triclosan glycosides could indeed be used in selective isolation plates as well as 
in broth cultures, MIC values were also determined in Nutrient Agar. Pleasingly, results were essentially the 
same as those obtained in broth (data not shown). As an example, to demonstrate the effectiveness of 
triclosan glycosides in isolation plates, recovery of Bacillus cereus in the presence of strains of 
staphylococci was investigated. Bacillus cereus is an important foodborne pathogen in humans causing 
severe nausea, vomiting, and diarrhoea (36). It is often present in samples with large numbers of other 
organisms and so can be difficult to isolate. PEMBA medium containing polymyxin B and cycloheximide 
with egg yolk precipitation as a presumptive identification is usually used (37).  The Bacillus and 
Staphylococcus strains were inoculated onto Nutrient Agar plates with and without 8 µg/ml triclosan-α-D-
glucopyranoside (3e). Although all strains grew well on Nutrient Agar only the Bacillus cereus strain could 
be recovered on plates containing the inhibitor (Figure 2) and its growth was not affected by free triclosan 
that may have been released from dead staphylocococcal cells; presumably amounts were too low or did not 
permeate through the agar.  
 
 
 
 
 
 
 
Figure 2. Nutrient agar plates inoculated with strains of Bacillus and Staphylococcus. Left, without and 
right with 8µg/ml triclosan-α-D-glucopyranoside (3e). Only the 2 Bacillus strains could be recovered on 
plates containing the inhibitor. 
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Conclusions 
Chemical derivatization of the antibacterial agent triclosan was optimised to afford four novel 
triclosan-α-D-glycopyranosides and three novel triclosan-β-D-glycopyranosides in generally very good 
yields, and excellent purities. The abilities of the glycosides to inhibit the growth of a broad range of gram-
positive and gram-negative bacterial organsisms, including many of clinical and industrial relevance, were 
probed and many were shown to be potent, selective, antibacterial agents. For example, β-galactoside (3a) 
and α-arabinoside (3c) had MIC values of 0.5 µg/ml for several strains of S. aureus and S. haemolyticus. 
Since Methicillin Resistant Staphylococcus aureus can be difficult to treat, and last resort compounds that 
may have toxic side-effects are often used, this is a significant advance. In addition, since antibacterial 
resistance in many cases is due to the production of high levels of β-lactamase, antibiotics with a different 
mode of activity such as those described herein are highly beneficial. Moreoever, as the glycoside 
derivatives prepared herein have increased aqueuous solubilities compared with free triclosan, as 
demonstrated by calculated logP values, this now provides opportunities for triclosan to be used perorally 
for the treatment of systemic infections.  
Since the novel glycosides were designed to be hydrolysed to afford triclosan in a bacteria dependent 
manner, based on the glycosidase profiles of the bacteria, their application for the selective recovery of 
bacteria from mixed bacterial populations was also explored. The activity of the triclosan glycosides was 
indeed generally found to be much more selective than the underivatized triclosan, and this was clearly 
demonstrated when considering the profiles of triclosan α-arabinoside (3c) and triclosan α-mannoside (3f). 
For the former, inclusion in selective recovery media at 1.0 µg/ml would allow recovery of Salmonella by 
inhibition of the growth of many of organisms that compete with Salmonella, such as strains of Enterobacter 
cloacae, Escherichia hermanii, Escherichia coli, Hafnia alvei, Klebsiella pneumoniae and Staphylococcus. 
Triclosan α-mannoside (3f) also demonstrated inhibition profiles that would be particularly useful for 
selective recovery, and hence identification, of Cronobacter sakazakii which is of particular concern when 
present in infant formula milk. In general, results from broth cultures were replicated in selective isolation 
plates that used Nutrient Agar No. 2. This was exemplified by recovery of two Bacillus strains from various 
strains of Bacillus and Staphylococcus after inoculation onto NA2 with 0.25 µg/ml triclosan-α-D-
glucopyranoside (3e).   This glucoside is, therefore, of use for the isolation of the food-poisoning organism 
Bacillus cereus. 
Taken together, these results therefore demonstrate that glycoside derivatives of triclosan offer 
considerable advantages as antibacterial agents compared with triclosan itself, specifically enhanced 
aqueous solubilities, targeted antibacterial profiles, and a mechanism of action that is complementary with 
those of existing antibacterial agents. These features have also allowed additional impact to be realised 
through the selective recovery of bacteria from mixed bacterial populations. 
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Materials and methods 
Analytical 
High Performance Liquid Chromatography (Agilent 1100 series) was used to determine the purity of the 
synthesised triclosan-α/β-D-glycopyranosides. A Primsep-B column (weak anion exchange, Hichrom, UK) 
was used and eluted with 0.1% formic acid and acetonitrile with a flow rate of 1.5 ml/min. Detection of 
triclosan (1) and triclosan-α/β-D-glycopyranosides was determined to be optimal at 275 nm. Calibration 
curves of both triclosan (1) and the triclosan-α/β-D-glycopyranosides (dissolved in H2O: Acetonitrile, 1:1) 
were constructed using a concentration range of 7.8 µg/ml to 1000µg/ml and used to determine the 
concentration of any triclosan (1) impurity.  
NMR spectra were recorded on a Bruker DPX 400 MHz instrument running ICON NMR 2.1 under 
TOPSPIN 1.3 at the University of Reading (Reading, UK). NMR spectra were analysed using MestreNova 
v.8.1.4-12489 software (Mestrelab, Santiago de Compostela, Spain). Samples were analysed in either 
deuterated chloroform (CDCl3) or dimethyl sulfoxide (DMSO-d6). Chemical shifts are quoted in parts per 
million using the abbreviations: s, singlet, d, doublet, at, apparent triplet, as, apparent singlet m, multiplet. 
All coupling constants are quoted to the nearest 0.5 Hz. 
 
Synthesis (25) 
General procedure A:  Glycosylation with 1M NaOH 
Triclosan (1) (1.06 eq.) was suspended in water (10.4 ml per mmol), 1M NaOH (1.06 eq) was then added. 
To this was added acetone (5.8 ml per mmol). Separately, acetobromo-derivative (1 eq.) was dissolved in 
acetone (6.2 ml per mmol). This solution was then added in one portion to the stirred solution of triclosan 
and sodium hydroxide and then stirred at room temperature for 18 hours. The reaction was then extracted 
with CH2Cl2, dried (MgSO4), and concentrated in vacuo. The crude product was then purified by column 
chromatography (eluent 3:2 hexane/ethyl acetate).  
Synthesis of O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-5-chloro-2-(2,4-
dichlorophenoxy)phenol (2a). Following general procedure A: Triclosan (1) (1.01 g, 3.5 mmol) was 
reacted with acetobromogalactose (1.36 g, 3.3 mmol) to yield (2a) as a clear oil (1 g, 49 %). [α]D20°C   -5.1 (c 
13.9, CHCl3). 1H NMR (400 MHz, CDCl3), 1.79 (3H, s, OAc), 1.90 (3H, s, OAc), 2.02 (3H, s, OAc), 2.09 
(3H, s, OAc), 3.61-4.39 (3H, m, H5, H6', H6), 4.96-5.04 (2H, m, H1, H3), 5.31 (1H, dd, J 10.5, 8.0 Hz, H2), 
5.36 (1H, dd, J 3.5, 1.0 Hz, H4), 6.64 (1H, d, J 9.0 Hz, H18), 6.74 (1H, d, J 8.5 Hz, H9), 6.96 (1H, dd, J 8.5, 
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2.5 Hz, H10), 7.07 (1H, dd, J 9.0, 2.5 Hz, H17), 7.22 (1H, d, J 2.5 Hz, H12), 7.37 (1H, d, J 2.5 Hz, H15). 
13C NMR (100 MHz, CDCl3), 20.3 (OAc), 20.5 (OAc), 20.6 (OAc), 20.6 (OAc), 61.7 (C6), 66.9 (C4), 68.2 
(C2), 70.6 (C3), 71.4 (C5), 100.1 (C1), 119.0 (C18), 119.8 (C12), 121.1 (C9), 124.2 (C10), 125.1 (ArQ), 
127.9 (C17), 128.6 (ArQ), 129.8 (ArQ), 130.4 (C15), 144.4 (ArQ), 148.1 (ArQ), 151.4 (ArQ)168.9 (OAc), 
169.9 (OAc), 170.1 (OAc), 170.4 (OAc). IR νmax/cm-1 (thin film), 3085 (C-H arene), 2971 (C-H), 1757 
(C=O), 1589 (C=C), 1367 (C-O), 1064 (C-C), 736 (C-C), 643 (C-Cl). FTMS (ESI, M+Na), 641.0338 
C26H25O11Cl3Na, req. 641.0355.  
Synthesis of O-(2,3,4,6-tetra-O-acetyl-β-D-glucopyranosyl)-5-chloro-2-(2,4-dichlorophenoxy)phenol 
(2b). Following general procedure A: Triclosan (1) (1.1 g, 3.8 mmol) was reacted with acetobromoglucose 
(1.47 g, 3.6 mmol) to yield (2b) as a clear oil (1 g, 45 %). [α]D20°C        -6.26 (c 4.6, CHCl3). 1H NMR (400 
MHz, CDCl3), 1.86 (3H, s, OAc), 2.00 (3H, s, OAc), 2.05 (3H, s, OAc), 2.12 (3H, s, OAc), 3.92-3.97 (1H, 
m, H5), 4.20-4.24 (2H, m, H6', H6), 5.10 (1H, app. t. J 8.0 Hz, H4), 5.13-5.18 (2H, m, H1, H2/3), 5.24-5.35 
(1H, m, H2/3), 6.71 (1H, d, J 9.0 Hz, H18), 6.86 (1H, d, J 8.5 Hz, H9), 7.05 (1H, dd, J 8.5, 2.5 Hz, H10), 
7.14 (1H, dd, J 9.0, 2.5 Hz, H17), 7.28 (1H, d, J 2.5 Hz, H12), 7.44 (1H, d, J 2.5 Hz, H15). 13C NMR (100 
MHz, CDCl3), 20.2 (OAc), 20.4 (OAc), 20.4 OAc), 20.6 (OAc), 62.0 (C6), 68.25 (C4), 70.7 (C2/3), 72.2 
(C5), 72.4 (C2/3), 99.26 (C1), 118.7 (C18), 119.0 (C12), 121.4 (C9), 124.1 (C10), 124.9 (ArQ), 127.8 
(C17), 128.5 (ArQ), 129.8 (ArQ), 130.3 (C15), 144.0 (ArQ), 148.1 (ArQ), 151.0 (ArQ), 168.8 (OAc), 169.3 
(OAc), 169.9 (OAc), 170.4 (OAc). IR νmax/cm-1 (thin film), 3069 (C-H arene), 2961 (C-H), 1746 (C=O), 
1594 (C=C), 1364 (C-O), 731 (C-C), 651 (C-Cl). FTMS (ESI, M+Na), 641.0334 C26H25O11Cl3Na, req. 
641.0355. 
Synthesis of O-(2,3,4-tri-O-acetyl-α-D-arabinopyranosyl)-5-chloro-2-(2,4-dichlorophenoxy)phenol 
(2c). Following general procedure A: Triclosan (1) (8.1 g, 28 mmol) was reacted with acetobromoarabinose 
(9.03 g, 26 mmol) to yield (2c) as a clear oil (1.78 g, 13 %). [α]D20°C +11 (c 0.9, CHCl3). 1H NMR (400 
MHz, CDCl3), 1.95 (3H, s, OAc), 1.99 (3H, s, OAc), 2.05 (3H, s, OAc), 3.72 (1H, dd, J 13.0, 2.5 Hz, H5'), 
4.09-4.15 (1H, m, H5), 5.10-5.12 (2H, m, H1, H2/H3), 5.27-5.31 (2H, m, H2/H3, H4), 6.73 (1H, d, J 9.0 Hz, 
H18), 6.79 (1H, d, J 8.5 Hz, H9), 7.03 (1H, dd, J 8.5, 2.5 Hz, H10), 7.16 (1H, dd, J 9.0, 2.5 Hz, H17), 7.26 
(1H, d, J 2.5 Hz, H12), 7.46 (1H, d, J 2.5 Hz, H15). 13C NMR (100 MHz, CDCl3), 20.5 (OAc), 20.6 (OAc), 
20.9 (OAc), 21.1 (OAc), 60.4 (C5), 66.7 (C2/C3/C4), 68.7 (C2/C3/C4), 69.2 (C2/C3/C4), 99.4 (C1), 119.2 
(C18), 120.0 (C12), 121.0 (C9), 124.2 (C10), 128.0 (C17), 130.5 (C15). IR νmax/cm-1 (thin film), 1748 
(C=O), 1636 (C=C), 1474 (C=C), 1371 (C-O), 1227 (C-O). FTMS (+ p APCI, M+Na) 569.0141 
C23H21O9Cl3Na req. 569.0143. FTMS (ESI, M+Na) 569.0141 C23H21O9Cl3Na req. 569.0143. 
General procedure B: Glycosylation with BF3.OEt2 
Under argon, the per-O-acetylated carbohydrate (1 eq.) was dissolved in anhydrous CH2Cl2. To this was 
added triclosan (1) (1.06 eq.). The reaction was then cooled to 0 °C and BF3.OEt2 (3 eq.) was then added. 
The reaction was then allowed to warm to room temperature and stirred for 18 hours. Water was then added 
to quench the reaction, which was then stirred for a further 15 minutes. The reaction was then diluted with 
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CH2Cl2, washed with water, brine, dried (MgSO4), filtered and concentrated in vacuo. The crude product 
was then purified by column chromatography (eluent 3:2 hexane/ethyl acetate) to yield the desired product.  
 
Synthesis of O-(2,3,4,6-tetra-O-acetyl-α-D-galactopyranosyl)-5-chloro-2-(2,4-
dichlorophenoxy)phenol (2d). Following general procedure B: 1,2,3,4,6-Penta-O-acetyl-β-D-
galactopyranoside (2 g, 5.12 mmol) was reacted with triclosan (1) (1.57 g, 5.43 mmol) in the presence of 
BF3.OEt2 (1.9 ml, 15.4 mmol) to yield (2d) as a clear oil (400 mg, 13 %). [α]D20°C +23 (c 1.1, CHCl3). 1H 
NMR (400 MHz, CDCl3), 1.91 (3H, s, OAc), 1.99 (3H, s, OAc), 2.03 (3H, s, OAc), 2.15 (3H, s, OAc), 4.09-
4.14 (2H, m, H6', H6), 4.28 (1H, app.t, J 7.0 Hz, H5), 5.18-5.25 (2H, m, H2, H3), 5.45-5.46 (1H, m, H4), 
5.80 (1H, d, J 3.0 Hz, H1), 6.77 (1H, d, J 9.0 Hz, H18), 6.89 (1H, d, J 8.5 Hz, H9), 7.04 (1H, dd, J 8.5, 2.5 
Hz, H10), 7.17 (1H, dd, J 9.0, 2.5 Hz, H17), 7.25 (1H, d, J 2.5 Hz, H12), 7.50 (1H, d, J 2.5 Hz, H15). 13C 
NMR (100 MHz, CDCl3), 20.4 (OAc), 20.5 (OAc), 20.5 (OAc), 20.9 (OAc), 61.7 (C6), 67.2 
(C2/C3/C4/C5), 67.4 (C2/C3/C4/C5), 67.6 (C2/C3/C4/C5), 67.6 (C2/C3/C4/C5), 95.8 (C1), 119.1 (C18), 
119.3 (C12), 121.2 (C9), 123.9 (C10), 125.2 (ArQ), 127.9 (C17), 128.9 (ArQ), 129.8 (ArQ), 130.7 (C15), 
144.7 (ArQ), 147.1 (ArQ), 151.6 (ArQ), 169.5 (OAc), 170.0 (OAc), 170.3 (OAc), 170.3 (OAc). IR νmax/cm-1 
(oil), 1757 (C=O), 1472 (C=C), 1370 (C-O), 1095 (C-O), 829 (C-H), 727 (C-Cl). FTMS (ESI, M+Na) 
641.0356 C26H25O11Cl3Na req. 641.0355. 
Synthesis of O-(2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl)-5-chloro-2-(2,4-dichlorophenoxy)phenol 
(2e). Following general procedure B: 1,2,3,4,6-Penta-O-acetyl-β-D-glucopyranside (500 mg, 1.28 mmol) 
was reacted with triclosan (1) (393 mg, 1.36 mmol) in the presence of BF3.OEt2 (0.5 ml, 3.84 mmol) to yield 
(2e)  as a clear oil (103 mg, 13 %). [α]D20°C +5.3 (c 0.5, CHCl3). 1H NMR (400 MHz, CDCl3) 1.94 (3H, s, 
OAc), 2.01 (3H, s, OAc), 2.05 (3H, s, OAc), 2.06 (3H, s, OAc), 3.88 (1H, ddd, J 10.0, 5.5, 2.0 Hz, H5), 4.03 
(1H, dd, J 12.0, 2.0 Hz, H6'), 4.17 (1H, dd, J 12.0, 5.5 Hz, H6), 4.92 (1H, dd, J 10.0, 3.5 Hz, H2), 5.02 (1H, 
dd, J 10.0, 9.5 Hz, H4), 5.16 (1H, app.t, J 9.5 Hz, H3), 5.73 (1H, d, J 3.5 Hz, H1), 6.71 (1H, d, J 9.0 Hz, 
H18), 6.97 (1H, d, J 8.5 Hz, H9), 7.06 (1H, dd, J 8.5, 2.5 Hz, H10), 7.15 (1H, dd, J 9.0, 2.5 Hz, H17), 7.21 
(1H, d, J 2.5 Hz, H12), 7.54 (1H, d, J 2.5 Hz, H15). 13C NMR (100 MHz, CDCl3), 20.5 (2 x OAc), 20.6 (2 x 
OAc), 61.8 (C6), 68.1 (C4), 68.3 (C5), 69.8 (C3), 70.2 (C2), 94.7 (C1), 118.4 (C12), 118.4 (C18), 121.9 
(C9), 123.9 (C10), 127.8 (C17), 131.1 (C15). IR νmax/cm-1 (oil), 1746 (C=O), 1599 (C=C), 1409 (C=C), 
1248 (C-O), 1023 (C-O), 849 (C-H), 812 (C-H), 757 (C-Cl). FTMS (ESI, M+Na) 641.0356 C26H25O11Cl3Na 
req. 641.0355. 
Synthesis of O-(2,3,4,6-tetra-O-acetyl-α-D-mannopyranosyl)-5-chloro-2-(2,4-
dichlorophenoxy)phenol (2f). Following general procedure B: 1,2,3,4,6-penta-O-acetyl-α/β-D-
mannopyranoside (5.0 g, 13 mmol) was reacted with triclosan (1) (3.99 g, 14 mmol) in the presence of 
BF3.OEt2 (4.8 ml, 39 mmol) to yield (2f) as a clear oil (3.39 g, 42 %). [α]D20°C +27.7 (c 1.3, CHCl3). 1H 
NMR (500 MHz, CDCl3), 1.98 (3H, s, OAc), 2.06 (3H,s OAc), 2.07 (3H, s, OAc), 2.15 (3H, s, OAc), 3.83 
(1H, ddd, J 10.0, 6.5, 2.0 Hz, H5), 4.05 (1H, dd, J 12.0, 2.0 Hz, H6), 4.18 (1H, dd, J 12.0, 6.5 Hz, H6), 4.89 
(1H, dd,  J 10.0 3.5 Hz, H3), 5.18-5.23 (2H, m, H2, H4), 5.51 (1H, d, J 1.8 Hz, H1), 6.70 (1H, d, J 9.0 Hz, 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
H18), 7.07-7.8 (2H, m. H9, H10), 7.16 (1H, dd, J 9.0, 2.5 Hz, H17), 7.26-7.27 (1H, m, H12), 7.49 (1H, d, J 
2.5 Hz, H15). 13C NMR (126 MHz, CHCl3), 20.3 (OAc), 20.4 (OAc), 20.5 (OAc), 20.5 (OAc), 62.0 (C6), 
65.5 (C2/C4), 68.2 (C3), 68.6 (C2/C4), 69.3 (C5), 95.9 (C1), 117.5 (C18/C12), 117.9 (C18/C12), 122.4 
(C9/C10), 123.6 (C9/C10), 124.4 (ArQ), 127.7 (C17), 128.1 (ArQ), 130.2 (ArQ), 130.8 (C15), 143.6 (ArQ), 
146.5 (ArQ), 152.0 (ArQ), 169.0 (OAc), 169.4 (OAc), 169.6 (OAc), 170.2 (OAc). IR νmax/cm-1 (oil), 1746 
(C=O), 1595 (C=C), 1475 (C=C), 1222 (C-O), 1045 (C-O), 829 (C-H), 822 (C-H), 812 (C-H), 608 (C-Cl). 
FTMS (ESI, M+Na) 569.0150 C23H21O9Cl3Na req. 569.0143. 
Synthesis of O-(2,3,4-tri-O-acetyl-β-D-arabinopyranosyl)-5-chloro-2-(2,4-dichlorophenoxy)phenol 
(2g). Following general procedure B: 1,2,3,4-tetra-O-acetyl-α/β-D-arabinpyranose/1,2,3,4-tetra-O-acetyl-
α/β-D-arabinofuranose (5.26 g, 17 mmol) was reacted with triclosan (1) (5.2 g, 18 mmol) in the presence of 
BF3.OEt2 (6.29 ml, 51 mmol) to yield (2g) as a clear oil (4.15 g, 45 %). [α]D20°C -53.6 (c 1.2, CHCl3). 1H 
NMR (400 MHz, CDCl3), 1.93 (3H, s, OAc), 2.01 (3H, s, OAc), 2.13 (3H, s, OAc), 3.74 (1H, dd, J 13.0, 2.0 
Hz, H5’), 3.96 (1H, app. d, J 12.5 Hz, H5), 5.17 (1H, dd, J 11.0, 3.5 Hz, H3), 5.25 (1H, dd, J 11.0, 3.5, H2), 
5.32-5.33 (1H, m, H4), 5.81 (1H, d, J 3.5 Hz, H1), 6.74 (1H, d, J 9.0 Hz, H18), 6.96 (1H, d, J 8.5 Hz, H9), 
7.03 (1H, dd, J 8.5, 2.5 Hz, H10), 7.15 (1H, dd, J 9.0, 2.5 Hz, H17), 7.23 (1H, d, J 2.5 Hz, H12), 7.49 (1H, 
d, J 2.5 Hz, H15). 13C NMR (100 MHz, CDCl3), 20.4 (OAc), 20.5 (OAc), 20.7 (OAc), 61.4 (C5), 66.8 (C3), 
67.52 (C2), 68.5 (C4), 95.9 (C1), 118.4 (C18/C12), 118.5 (C18/C12), 121.8 (C9), 123.5 (C10), 124.8 (ArQ), 
127.6 (C17), 128.4 (ArQ), 130.2 (ArQ), 130.6 (C15), 144.2 (ArQ), 147.5 (ArQ), 151.9 (ArQ), 169.4 (OAc), 
169.9 (OAc), 170.2 (OAc). IR νmax/cm-1 (oil), 1745 (C=O), 1599 (C=C), 1495 (C=C), 1248 (C-O), 1095 (C-
O), 862 (C-H), 800 (C-H), 709 (C-Cl). FTMS (ESI, M+Na) 569.0150 C23H21O9Cl3Na req. 569.0143. 
General procedure C: Deprotections 
Under argon, the protected sugar (1eq) was dissolved in anhydrous MeOH (1 ml per mmol). K2CO3 (0.1 
eq) was then added. The reaction was then stirred until it was deemed to be complete as evidenced by TLC 
analysis. Amberlite IR-120 (plus) resin was then added and the reaction was stirred for a further 30 minutes. 
The resin was then filtered off and the filtrate concentrated in vacuo to yield the desired product.  
Synthesis of triclosan-β-D-galactopyranoside (3a). Following general procedure C: O-(2,3,4,6-tetra-O-
acetyl-β-D-galactopyranosyl)-5-chloro-2-(2,4-dichlorophenoxy)phenol (2a) (715 mg, 1.15 mmol) was 
reacted with potassium carbonate (16 mg, 0.115 mmol) to yield (3a) as an amorphous foam (429 mg, 83 %). 
[α]D20°C -28.29 (c 0.35, MeOH). 1H NMR (400 MHz, MeOD), 3.59 (1H, dd, J 10.0, 3.0 Hz, H3), 3.66-3.80 
(4H, m, H6', H6, H2, H5), 3.91 (1H, app. d, J 3.0 Hz, H4), 4.98 (1H, d, J 8.0 Hz, H1), 6.85 (1H, d, J 9.0 Hz, 
H18), 6.87 (1H, d, J 8.5 Hz, H9), 7.02 (1H, dd, J 8.5 Hz, 2.5 Hz, H10), 7.22 (1H, dd, J 9.0, 2.5 Hz, H17), 
7.38 (1H, d, J 2.5 Hz, H12), 7.49 (1H, d, J 2.5 Hz, H15). 13C NMR (100 MHz, MeOD), 62.3 (C6), 70.1 
(C4), 72.1 (C2/5), 74.9 (C3), 77.1 (C2/5), 103.0 (C1), 119.3 (C12), 120.9 (C18), 122.5 (C9), 124.0 (C10), 
126.2 (ArQ), 129.4 (C17), 129.62 (ArQ), 131.2 (C15), 131.26 (ArQ), 145.5 (ArQ), 150.6 (ArQ), 153.4 
(ArQ). IR νmax/cm-1 (thin film), 3391 (OH), 1652 (C=C), 1449 (C=C), 1026 (C-O), 668 (C-Cl). FTMS (ESI, 
M+Na), 472.9914 C18H17O7Cl3Na, req. 472.9932. 
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Synthesis of triclosan-β-D-glucopyranoside (3b). Following general procedure C: O-(2,3,4,6-tetra-O-
acetyl-β-D-glucopyranosyl)-5-chloro-2-(2,4-dichlorophenoxy)phenol (2b) (500 mg, 0.81 mmol) was reacted 
with potassium carbonate (11 mg, 0.081 mmol) to yield (3b) as an amorphous foam (258 mg, 71 %). 
[α]D20°C -21 (c 0.5, MeOH). 1H NMR (400 MHz, MeOD), 3.27-3.53 (4H, m, H2, H3, H4, H5), 3.70 (1H, dd, 
J 12.0, 5.5 Hz, H6'), 3.88 (1H, dd, J 12.0, 2.0 Hz, H6), 5.04 (1H, d, J 8.0 Hz, H1), 6.85 (1H, d, J 9.0 Hz, 
H18), 6.88 (1H, d, J 8.5 Hz, H9), 7.03 (1H, dd, J 8.5, 2.5 Hz, H10), 7.22 (1H, dd, J 9.0, 2.5 Hz, H17), 7.36 
(1H, d, J 2.5 Hz, H12), 7.49 (1H, d, J 2.5 Hz, H15). 13C NMR (100 MHz, MeOD), 62.4 (C6), 71.1 
(C2/3/4/5), 74.8 (C2/3/4/5), 78.0 (C2/3/4/5), 78.3 (C2/3/4/5), 102.3 (C1), 119.3 (C12), 120.9 (C18), 122.5 
(C9), 124.1 (C10), 126.2 (ArQ), 129.4 (C17), 129.6 (ArQ), 131.2 (C15), 131.3 (ArQ), 145.5 (ArQ), 150.4 
(ArQ), 153.4 (ArQ). IR νmax/cm-1 (thin film), 3411 (OH), 1652 (C=C), 1450 (C=C), 1031 (C-O), 758 (C-C). 
FTMS (ESI, M+Na), 472.9924 C18H17O7Cl3Na, req. 472.9932. 
 
Synthesis of triclosan-α-D-arabinopyranoside (3c). Following general procedure C: O-(2,3,4-tri-O-
acetyl-α-D-arabinopyranosyl)-5-chloro-2-(2,4-dichlorophenoxy)phenol (2c) (1.47 g, 2.69 mmol) was reacted 
with potassium carbonate (37 mg, 0.269 mmol) to yield (3c) as an amorphous foam (1.195 g, 99 %). [α]D20°C 
+17.6 (c 1.1, MeOH). 1H NMR (400 MHz, MeOD), 3.63 (1H, dd, J 8.5, 3.5 Hz, H3), 3.71 (1H, dd, J 12.5, 
2.0 Hz, H5'), 3.74 (1H, dd, J 8.5, 6.5 Hz, H2), 3.86-3.89 (1H, m, H4), 3.93 (1H, dd, J 12.5, 3.5 Hz, H5), 5.00 
(1H, d, J 6.5 Hz, H1), 6.84 (1H, d, J 9.0 Hz, H18), 6.92 (1H, d, J 8.5 Hz, H9), 7.06 (1H, dd, J 8.5, 2.5 Hz, 
H10), 7.25 (1H, dd, J 9.0, 2.5 Hz, H17), 7.32 (1H, d, J 2.5 Hz, H12), 7.53 (1H, d, J 2.5 Hz, H15). 13C NMR 
(100 MHz, MeOD), 66.8 (C5), 69.1 (C4), 72.0 (C2), 73.9 (C3), 102.7 (C1), 119.5 (C12), 120.6 (C18), 122.6 
(C9), 124.1 (C10), 126.3 (ArQ), 129.3 (C17), 129.8 (ArQ), 131.2 (C15), 145.7 (ArQ), 150.2 (ArQ), 153.3 
(ArQ). IR νmax/cm-1 (solid), 3359 (O-H), 1595 (C=C), 1471 (C=C), 1223 (C-C), 1067 (C-C), 1011 (C-C), 
906 (C-H), 778 (C-Cl). FTMS (ESI, M+Na) 442.9824 C17H15O6Cl3Na, req.442.9826. 
 
Synthesis of triclosan-α-D-galactopyranoside (3d). Following general procedure C: O-(2,3,4,6-tetra-O-
acetyl-α-D-galactopyranosyl)-5-chloro-2-(2,4-dichlorophenoxy)phenol (2d) (432 mg, 0.7 mmol) was reacted 
with potassium carbonate (10 mg, 7 x 10-5 mol) to yield (3d)  as an orange oil (166 mg, 37 %). [α]D20°C 
+88.6 (c 1.3, MeOH). 1H NMR (400 MHz, MeOD), 3.56 (1H, dd, J 10.0, 3.5 Hz, H3), 3.65-3.66 (2H, m, 
H6', H6), 3.74-3.78 (1H, m, H5), 3.85 (1H, dd, J 3.5, 1.5 Hz, H4), 3.92 (1H, dd, J 10.0, 3.5 Hz, H2), 5.34 
(1H, d, J 3.5 Hz, H1), 3.92 (1H, d, J 9.0 Hz, H18), 7.01 (1H, d, J 8.5 Hz, H9), 7.07 (1H, dd, J 8.5, 2.5 Hz, 
H10), 7.23 (1H, dd, J 8.5, 2.5 Hz, H12), 7.43 (1H, d, J 2.5 Hz, H12), 7.53 (1H, d, J 2.5 Hz, H15). 13C NMR 
(100 MHz, MeOD), 62.4 (C6), 69.7 (C2), 70.7 (C4), 71.2 (C3), 73.8 (C5), 100.0 (C1), 119.4 (C12), 119.8 
(C18), 123.3 (C9/C10), 124.0 (C9/C10), 125.6 (ArQ), 129.3 (C17), 131.3 (C15), 131.7 (ArQ), 145.4 (ArQ), 
150.0 (ArQ x 2), 153.8 (ArQ). IR νmax/cm-1 (solid), 3358 (O-H), 2935 (C-H), 1569 (C=C), 1491 (C=C), 
1259 (C-C), 1073 (C-C), 949 (C-C), 866 (C-H), 754 (C-Cl). FTMS (ESI, M+Na) 472.9930 C18H17O7Cl3Na, 
req. 472.9932. 
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Synthesis of triclosan-α-D-glucopyranoside (3e). Following general procedure C: O-(2,3,4,6-tetra-O-
acetyl-α-D-glucopyranosyl)-5-chloro-2-(2,4-dichlorophenoxy)phenol (2e) (345 mg, 0.56 mmol) was reacted 
with potassium carbonate (8 mg 5.6 x 10-5 mol) to yield (3e) as an amorphous foam (250 mg, 99 %). 
[α]D20°C +7.9 (c 12.5, MeOH). 1H NMR (400 MHz, MeOD), 3.44 (1H, dd, J 10.5, 8.5 Hz, H3/H4), 3.56-3.72 
(5H, m, H6', H6, H2/H3/H4/H5), 5.59 (1H, d, J 3.0 Hz, H1), 6.83 (1H, d, J 9.0 Hz, H18), 6.94 (1H, d, J 8.5 
Hz, H9), 7.05 (1H, dd, J 8.5, 2.5 Hz, H10), 7.23 (1H, dd, J 9.0, 2.5 Hz, H17), 7.44 (1H, d, J 2.5 Hz, H12), 
7.50 (1H, d, J 2.5, H15). 13C NMR (100, MeOD), 62.1 (C6), 70.9 (C2/C3/C4/C5), 73.1 (C2/C3/C4/C5), 74.7 
(C2/C3/C4/C5), 75.0 (C2/C3/C4/C5), 100.4 (C1), 119.8 (C12), 120.2 (C18), 122.8 (C9), 124.8 (C10), 125.9 
(ArQ), 129.4 (C17), 131.3 (C15), 131.4 (ArQ), 145.8 (ArQ), 150.2 (ArQ), 153.5 (ArQ). IR νmax/cm-1 (solid), 
3356 (O-H), 2938 (C-H), 1569 (C=C), 1471 (C=C), 1224 (C-C), 1056 (C-C), 863 (C-H), 783 (C-Cl). FTMS 
(ESI, M+Na) 472.9929 C18H17O7Cl3Na, req.472.9932. 
Synthesis of triclosan-α-D-mannopyranoside (3f). Following general procedure C: O-(2,3,4,6-tetra-O-
acetyl-α-D-mannopyranosyl)-5-chloro-2-(2,4-dichlorophenoxy)phenol (2f) (381 mg, 0.6 mmol) was reacted 
with potassium carbonate (8.5 mg, 0.06 mmol) to yield (3f) as an amorphous foam (246 mg, 89 %).  [α]D20°C 
+41.9 (c 0.82, MeOH). 1H NMR (400 MHz, MeOD), 3.46-3.76 (6H, m, H2, H3, H4, H5, H6, H6’), 5.45 
(1H, d, J 1.5 Hz, H1), 6.75 (1H, d, J 9.0 Hz, H18), 7.06-707 (2H, m, H9, H10), 7.21 (1H, dd, J 9.0, 2.5 Hz, 
H17), 7.48 (1H, d, J 2.5 Hz, H12), 7.51 (1H, d, J 2.5 Hz, H15). 13C NMR (100 MHz, MeOD), 62.5 (C6), 
68.0 (C2/C3/C4/C5), 71.6 (C2/C3/C4/C5), 72.2 (C2/C3/C4/C5), 75.8 (C2/C3/C4/C5), 101.2 (C1), 119.2 
(C18), 119.5 (C12), 123.6 (C10/C9), 124.2 (C10/9), 125.4 (ArQ), 129.3 (ArQ), 129.3 (C17), 131.3 (C15), 
131.8 (ArQ), 145.0 (ArQ), 149.8 (ArQ), 153.9 (ArQ). IR νmax/cm-1 (solid), 3325 (O-H), 2933 (C-H), 1597 
(C=C), 1490 (C=C) 1258 (C-O), 1098 (C-C), 1000 (C-C), 751 (C-Cl). FTMS (ESI, M+Na) 472.9930 
C18H17O7Cl3Na, req.472.9932. 
 
Synthesis of triclosan-β-D-arabinopyranoside (3g). Following general procedure C: O-(2,3,4-tri-O-
acetyl-β-D-arabinopyranosyl)-5-chloro-2-(2,4-dichlorophenoxy)phenol (2g) (3.5g, 6.4 mmol) was reacted 
with potassium carbonate (88 mg, 0.64 mmol) to yield (3g) as an amorphous foam (2.37 g, 88 %). [α]D20°C -
56.4 (c 0.85, MeOH). 1H NMR (400 MHz, MeOD), 3.61 (1H, dd, J 12.5, 2.0 Hz, H5’), 3.63 (1H, dd, J 10.0, 
3.5 Hz, H3), 3.76 (1H, dd, J 12.5, 1.0 Hz, H5), 3.81-3.82 (1H, m, H4), 3.95 (1H, dd, J 10.0, 3.5 Hz, H2), 
5.64 (1H, d, J 3.5 Hz, H1), 6.78 (1H, d, J 9.0 Hz, H18), 6.99 (1H, d, J 8.5 Hz, H9), 7.05 (1H, dd, J 8.5, 2.5 
Hz, H10), 7.20 (1H, dd, J 9.0, 2.5 Hz, H17), 7.35 (1H, d, J 2.5 Hz, H12), 7.50 (1H, d, J 2.5 Hz, H15). 13C 
NMR (100 MHz, MeOD), 65.6 (C5), 69.7 (c2), 70.5 (C4), 70.6 (C3), 100.6 (C1), 119.5 (C12), 119.8 (C18), 
123.4 (C9), 124.1 (C10), 125.6 (ArQ), 129.3 (C17), 129.5 (ArQ), 131.3 (C15), 131.7 (ArQ), 145.5 (ArQ), 
150.0 (ArQ), 153.7 (ArQ). IR νmax/cm-1 (solid), 3360 (O-H), 2931 (C-H), 1596 (C=C), 1224 (C-O), 1076 (C-
C), 999 (C-C), 756 (C-Cl). FTMS (ESI, M+Na) 442.9824 C17H15O6Cl3Na, req.442.9826. 
 
Bacterial strains.  All strains were from the American Type Culture Collection (ATCC University 
Boulevard, Manassas, VA, USA) except as indicated NCTC (National Collection of Type Cultues, Public 
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Health England, Porton Down, Salisbury, UK), OCC (Oxoid Culture Collection (Thermofisher Scientific, 
Wade Road, Basingstoke, UK). Gram negative: Aeromonas hydrophila OCC 778, Citrobacter freundii 
8090, OCC 851, Enterobacter aerogenes 13048, Enterobacter cloacae 13047, Cronobacter sakazakii 
29544, Escherichia coli 8739, 10536, 11775, 25922, 35218, 700728, NCTC 13216, OCC 122, Escherichia 
hermanii 33650, Hafnia alvei 13337, Klebsiella aerogenes NCTC 8167, Klebsiella pneumoniae 10031, 
13883, Proteus mirabilis 12453, Proteus vulgaris OCC 195, Pseudomonas aeruginosa 27853, Salmonella 
enterica subspecies enterica serotypes: Abony NCTC 6017, Arizonae OCC 706, Dublin OCC 627, Enteritidis 
13076, Indiana OCC 597, Infantis OCC 2133, Nottingham NCTC 7832, Poona NCTC 4840, Pullorum OCC 
273, Typhimurium 14028 and Virchow NCTC 5742, Serratia marcescens OCC 217. Gram positive: Bacillus 
cereus 14579, Bacillus subtilis NCTC 10073, Enterococcus faecalis 29212, 33186, Enterococcus faecium 
19434, Staphylococcus aureus 6538, 6538P, 9144, 25923, 29213, NCTC 13758, OCC 104, OCC 106, 
Staphylococcus epidermidis 155, 12228, 14990, Staphylococcus haemolyticus OCC 2223, Staphylococcus 
saprophyticus 15305, Streptococcus agalactiae OCC 182, Streptococcus pneumoniae 6305, 49619, 
Streptococcus pyogenes 19615, Streptococcus viridans OCC 234. 
 
MIC determination in broth growth medium. Triclosan and its glycosides were dissolved in ethanol 
then amounts of these stock solutions diluted in Nutrient Broth (NB2; “Oxoid”, ThermoFisher, Basingstoke, 
UK) to give concentrations of 0.01µg/ml to 128µg/ml for triclosan and 0.25µg/ml to 256µg/ml for its 
glycosides. Volumes (180µl) were then added to wells of microtitre plates. Bacteria were grown overnight at 
37oC in NB2 from plate inoculum. Cultures were diluted 1 in 104 in saline and 20µl amounts added to the 
triclosan/ triclosan glycoside solutions. Once filled, plates were covered, placed in a Bioscreen C MBR 
instrument (Oy Growth Curves Ab Ltd. Helsinki, Finland), incubated at 37oC and optical density (OD) of 
each well measured every 15 minutes after agitation. The minimum inhibitory concentration (MIC) of a 
compound was defined as the lowest concentration of inhibitor that was required to eliminate an increase in 
OD after 18 hours incubation at 37oC. 
 
MIC determination on agar plates. Amounts of triclosan glycoside solutions prepared as described 
above were added to Nutrient Agar (NA2; “Oxoid”, ThermoFisher) and the media autoclaved for 15 minutes 
at 121oC. Plates were poured, dried and stored at 4oC using within one week of pouring. Cultures were 
prepared as above, diluted 1 in 102 in saline and inoculated onto plates using an “Oxoid” replicator system. 
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Highlights 
 
• Synthesis and characterisation of four α-D-glycopyranosides and three β-D-
glycopyranosides of the broad antibacterial agent triclosan, in generally very good 
synthetic yields, and with excellent purities 
• All of the triclosan glycosides that were synthesized demonstrated antibacterial 
activity against many of the organisms that were examined. 
• β-Galactoside (3a) and α-arabinoside (3c) had MIC values of 0.5 µg/ml for several 
strains of S. aureus and S. haemolyticus. 
• Two Bacillus strains could be identified from various strains of Bacillus and 
Staphylococcus after inoculation onto Nutrient Agar No. 2 with 0.25 µg/ml triclosan-
α-D-glucopyranoside (3e) 
 
 
